Clinical management and outcome of 36 invasive prolactinomas treated with dopamine agonist

Journal of Neuro-Oncology

Volumn 104, Issue 1, 2011, Pages 195-204

  Yang, Moon Sool ^a   Hong, Jae Won ^a   Lee, Seung Koo ^a   Lee, Eun Jig ^a   Kim, Sun Ho ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Bromocriptine; Cabergoline; Dopamine; Hyperprolactinemia; Invasive prolactinoma

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; PROLACTIN;

ADULT; ARTICLE; BEDTIME DOSAGE; CLINICAL ARTICLE; DRUG MEGADOSE; FEMALE; FOLLOW UP; GAMMA KNIFE RADIOSURGERY; HUMAN; INVASIVE PROLACTINOMA; LOW DRUG DOSE; MALE; PROLACTIN BLOOD LEVEL; PROLACTINOMA; RETROSPECTIVE STUDY; SYMPTOM; TRANSSPHENOIDAL SURGERY; TREATMENT RESPONSE; TUMOR VOLUME;

ADULT; BROMOCRIPTINE; DOPAMINE AGONISTS; FEMALE; HEADACHE; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PERCEPTUAL DISORDERS; PITUITARY NEOPLASMS; PROLACTIN; PROLACTINOMA; RETROSPECTIVE STUDIES; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; VISUAL FIELDS; YOUNG ADULT;

EID: 80052744008     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0459-3     Document Type: Article

References (37)

1. S Franks HS Jacobs JD Nabarro 1975 Proceedings: studies of prolactin secretion in pituitary disease J Endocrinol 67 55P 1206303 1:STN:280: DyaE28%2Fps1eksg%3D%3D
2. WY Jeon OL Kim SH Kim JH Bae BY Choi SH Cho 2001 The surgical result of pituitary adenoma by transsphenoidal approach J Korean Neurosurg Soc 30 1278 1283
3. JL Hubbard BW Scheithauer CF Abboud ER Laws 1987 Prolactin-secreting adenomas: the preoperative response to bromocriptine treatment and surgical outcome J Neurosurg 67 816 821 3681421 10.3171/jns.1987.67.6.0816 1:STN:280:DyaL1c%2FmtFGquw%3D%3D (Pubitemid 18005525)
4. DL Barrow J Mizuno GT Tindall 1988 Management of prolactinomas associated with very high serum prolactin levels J Neurosurg 68 554 558 3351583 10.3171/jns.1988.68.4.0554 1:STN:280:DyaL1c7ntFKksw%3D%3D
5. ME Molitch 2002 Medical management of prolactin-secreting pituitary adenomas Pituitary 5 55 65 12675502 10.1023/A:1022375429083 1:CAS:528: DC%2BD3sXhtVOlurg%3D (Pubitemid 36336010)
6. ME Molitch RL Elton RE Blackwell B Caldwell RJ Chang R Jaffe G Joplin RJ Robbins J Tyson MO Thorner 1985 Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study J Clin Endocrinol Metab 60 698 705 3882737 10.1210/jcem-60-4-698 1:STN:280:DyaL2M7jtFKiuw%3D%3D (Pubitemid 15147556)
7. JJ Pinzone L Katznelson DC Danila DK Pauler CS Miller A Klibanski 2000 Primary medical therapy of micro- and macroprolactinomas in men J Clin Endocrinol Metab 85 3053 3057 10999785 10.1210/jc.85.9.3053 1:CAS:528: DC%2BD3cXmsVKruro%3D
8. BE Pollock J Cochran N Natt PD Brown D Erickson MJ Link YI Garces RL Foote SL Stafford PJ Schomberg 2008 Gamma knife radiosurgery for patients with nonfunctioning pituitary adenomas: results from a 15-year experience Int J Radiat Oncol Biol Phys 70 1325 1329 18029107 10.1016/j.ijrobp.2007.08.018 (Pubitemid 351417753)
9. GT Tindall CS McLanahan JH Christy 1978 Transsphenoidal microsurgery for pituitary tumors associated with hyperprolactinemia J Neurosurg 48 849 860 207832 10.3171/jns.1978.48.6.0849 1:STN:280:DyaE1c7ps1Wlug%3D%3D (Pubitemid 8353723)
10. JB Tyrrell KR Lamborn LT Hannegan CB Applebury CB Wilson 1999 Transsphenoidal microsurgical therapy of prolactinomas: initial outcomes and long-term results Neurosurgery 44 254 261 9932878 10.1097/00006123-199902000- 00006 1:STN:280:DyaK1M7ivFKmug%3D%3D (Pubitemid 29068168)
11. N Saeki M Nakamura K Sunami A Yamaura 1998 Surgical indication after bromocriptine therapy on giant prolactinomas: effects and limitations of the medical treatment Endocr J 45 529 537 9881903 10.1507/endocrj.45.529 1:CAS:528:DyaK1cXntleht7s%3D (Pubitemid 28477665)
12. C Yu Z Wu J Gong 2005 Combined treatment of invasive giant prolactinomas Pituitary 8 61 65 16411070 10.1007/s11102-005-5087-0 1:CAS:528: DC%2BD28XksVOgtA%3D%3D (Pubitemid 44680087)
13. E Ciccarelli F Camanni 1996 Diagnosis and drug therapy of prolactinoma Drugs 51 954 965 8736617 10.2165/00003495-199651060-00004 1:CAS:528: DyaK28XktF2lsbY%3D (Pubitemid 26164165)
14. Y Iwai A Hakuba VK Khosla M Nishikawa J Katsuyama Y Inoue S Nishimura 1992 Giant basal prolactinoma extending into the nasal cavity Surg Neurol 37 280 283 1595040 10.1016/0090-3019(92)90153-E 1:STN:280:DyaK383nvF2jtg%3D%3D
15. RK Shrivastava MS Arginteanu WA King KD Post 2002 Giant prolactinomas: clinical management and long-term follow up J Neurosurg 97 299 306 12186457 10.3171/jns.2002.97.2.0299 (Pubitemid 34827329)
16. ZB Wu CJ Yu ZP Su QC Zhuge JS Wu WM Zheng 2006 Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up J Neurosurg 104 54 61 16509147 10.3171/jns.2006.104.1.54 1:CAS:528:DC%2BD28Xnt12ltQ%3D%3D
17. A Colao A Di Sarno F Sarnacchiaro D Ferone G Di Renzo B Merola L Annunziato G Lombardi 1997 Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment J Clin Endocrinol Metab 82 876 883 9062500 10.1210/jc.82.3.876 1:CAS:528:DyaK2sXhsl2iu7c%3D (Pubitemid 27106605)
18. MP Gillam ME Molitch G Lombardi A Colao 2006 Advances in the treatment of prolactinomas Endocr Rev 27 485 534 16705142 10.1210/er.2005-9998 1:CAS:528:DC%2BD28XpvVelurY%3D (Pubitemid 44213229)
19. J Corvol J Anzouan-Kacou E Fauveau A Bonnet B Lebrun-Vignes C Girault Y Agid P Lechat R Isnard L Lacomblez 2007 Heart valve regurgitation, pergolide use, and Parkinson disease: an observational study and meta-analysis Arch Neurol 64 1721 1726 18071034 10.1001/archneur.64.12.1721 (Pubitemid 350254933)
20. R Zanettini A Antonini G Gatto R Gentile S Tesei G Pezzoli 2007 Valvular heart disease and the use of dopamine agonists for Parkinson's disease N Engl J Med 356 39 46 17202454 10.1056/NEJMoa054830 1:CAS:528:DC%2BD2sXitlCgsQ%3D%3D (Pubitemid 46041752)
21. A Antonini W Poewe 2007 Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease Lancet Neurol 6 826 829 17706566 10.1016/S1474-4422(07)70218-1 1:CAS:528:DC%2BD2sXhtVyrsrrP (Pubitemid 47243713)
22. M Kars V Delgado ER Holman RA Feelders JW Smit JA Romijn J Bax AM Pereira 2008 Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma J Clin Endocrinol Metab 93 3348 3356 18559921 10.1210/jc.2007-2658 1:CAS:528:DC%2BD1cXhtFChurvE
23. M Kars AM Pereira JJ Bax JA Romijn 2008 Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required Eur J Endocrinol 159 363 367 18703568 10.1530/EJE-08-0611 1:CAS:528:DC%2BD1cXhtlSrtLbE
24. A Colao M Galderisi A Di Sarno M Pardo M Gaccione M D'Andrea E Guerra R Pivonello G Lerro G Lombardi 2008 Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline J Clin Endocrinol Metab 93 3777 3784 18682513 10.1210/jc.2007-1403 1:CAS:528:DC%2BD1cXht1Gmur%2FM
25. TJ Cawood P Bridgman L Hunter D Cole 2009 Low-dose cabergoline causing valvular heart disease in a patient treated for prolactinoma Inter Med J 39 266 267 10.1111/j.1445-5994.2009.01920.x 1:STN:280:DC%2BD1MzhtVWhsg%3D%3D
26. E Knosp E Steiner K Kitz C Matula 1993 Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings Neurosurgery 33 610 617 8232800 10.1227/00006123-199310000-00008 1:STN:280:DyaK2c%2FltVCnsQ%3D%3D
27. G Di Chiro KB Nelson 1962 The volume of the sella turcica Am J Roentgenol Radium Ther Nucl Med 87 989 1008 13885978 1:STN:280:DyaF38%2FislaqsQ%3D%3D
28. DK Hamilton ML Vance PT Boulos ER Laws 2005 Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists Pituitary 8 53 60 16411069 10.1007/s11102-005- 5086-1 (Pubitemid 44680086)
29. M Fleseriu M Lee M Pineyro M Skugor SK Reddy ES Siraj AH Hamrahian 2006 Giant invasive pituitary prolactinoma with falsely low serum prolactin: the significance of 'hook effect' J Neurooncol 79 41 43 16598425 10.1007/s11060-005-9108-7 (Pubitemid 44057415)
30. P Pakzaban 2000 Giant prolactinoma and hook effect Neurology 55 1415 1416 11087799 1:STN:280:DC%2BD3M%2FlvFymuw%3D%3D
31. ME Molitch 2003 Dopamine resistance of prolactinomas Pituitary 6 19 27 14674720 10.1023/A:1026225625897 1:CAS:528:DC%2BD3sXotlajs74%3D (Pubitemid 37455641)
32. ME Molitch 2005 Pharmacologic resistance in prolactinoma patients Pituitary 8 43 52 16411068 10.1007/s11102-005-5085-2 1:CAS:528: DC%2BD28XksVOgtw%3D%3D (Pubitemid 44680085)
33. ME Molitch 2006 Prolactin-secreting tumors: what's new? Expert Rev Anticancer Ther 6 Suppl 9 S29 S35 10.1586/14737140.6.9s.S29 17004854 10.1586/14737140.6.9s.S29
34. MJ Kupersmith D Kleinberg FA Warren G Budzilovitch P Cooper 1989 Growth of prolactinoma despite lowering of serum prolactin by bromocriptine Neurosurgery 24 417 423 2927618 10.1227/00006123-198903000-00020 1:STN:280:DyaL1M7ot1CgsA%3D%3D (Pubitemid 19090402)
35. AM Landolt V Osterwalder 1984 Perivascular fibrosis in prolactinomas: is it increased by bromocriptine? J Clin Endocrinol Metab 58 1179 1183 6725514 10.1210/jcem-58-6-1179 1:STN:280:DyaL2c3ht12qtA%3D%3D (Pubitemid 14084037)
36. JW Hong MK Lee Sh Kim EJ Lee 2010 Discrimination of prolactinoma from hyperprolactinemic non-functioning adenoma Endocrine 37 140 147 20963563 10.1007/s12020-009-9279-7 1:CAS:528:DC%2BC3cXpsFGrsg%3D%3D
37. A Colao C Di Somma R Pivonello A Faggiano G Lombardi S Savastano 2008 Medical therapy for clinically non-functioning pituitary adenomas Endocr Relat Cancer 15 905 915 18780796 10.1677/ERC-08-0181 1:CAS:528:DC%2BD1MXitVyrsL8%3D